Health
Tiotropium Respimat Improves Lung Function In Asthmatic Children

By Modupe Gbadeyanka
Boehringer Ingelheim announced today new study results from the Phase III CanoTinA-asthma® trial showing that the addition of Tiotropium Respimat® to the maintenance asthma therapy significantly improved lung function, as measured by FEV1(0-3h), in children aged 6-11, compared to placebo (p<0.0001).1
These findings were presented today at the European Respiratory Society (ERS) International Congress 2016 in London.
The trial investigated tiotropium Respimat® as an add-on therapy for children who were already taking an inhaled corticosteroid (ICS), or an ICS combined with other maintenance therapy.1,2 In this study, the safety and tolerability of tiotropium Respimat® were shown to be comparable to placebo.
“Asthma is the most common chronic childhood disease, but many children still continue to experience asthma symptoms despite taking other maintenance therapies,” said Professor Christian Vogelberg, University Hospital Dresden, Germany.
A new pooled analysis from four studies, VivaTinA-asthma®, RubaTinA-asthma®, PensieTinA-asthma® and CanoTinA-asthma® also presented at ERS, showed adding tiotropium Respimat® to maintenance therapy for children aged 6-17 years has a comparable safety profile to placebo.3 In addition, this analysis showed tiotropium Respimat® significantly improved peak expiratory flow (PEF), a common measure of asthma control.
“These new results showed significant lung function improvements for children with asthma and importantly confirm that the safety profile of tiotropium Respimat® in children aged six years and above is comparable to placebo,” said Professor Vogelberg.
In the important subgroup of children aged 1-5, a new post-hoc analysis presented from the NinoTinA-asthma® trial showed the safety profile of adding tiotropium Respimat® to maintenance therapy is consistent with that found in older children and adults.
The CanoTinA-asthma®, NinoTinA-asthma®, VivaTinA-asthma®, RubaTinA-asthma® and PensieTinA-asthma® trials are part of the 18 clinical studies from the Phase II and Phase III UniTinA-asthma® clinical development program, which included more than 150 sites globally with over 6,000 patients, including over 1,800 children and adolescents aged 1-17 years.
“At Boehringer Ingelheim, we have a strong commitment to scientific research with the goal of improving the care of people living with serious respiratory diseases such as asthma,” said Dr William Mezzanotte, Vice President and Head of Respiratory Medicine at Boehringer Ingelheim. “Data from these studies build on the body of evidence that we have learned about tiotropium Respimat® as an add-on therapy for asthma.”
SPIRIVA® (tiotropium) Respimat® 5µg is indicated in Europe as an add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of ICS (≥800µg budesonide/day or equivalent) and long-acting β2 agonists (LABA) and who experienced one or more severe exacerbations in the previous year.
Tiotropium is an inhaled long-acting, muscarinic antagonist. It works by opening airways and helps to keep them open for at least 24 hours.
SPIRIVA® Respimat® is currently NOT APPROVED for use in children and adolescents under 18 years of age in the EU, or in children under 12 years in the US. SPIRIVA® Respimat® has been approved for use in asthma in over 50 countries, including the EU, US and Japan. The indication varies by country. Please refer to the local product information.
Health
Lagos Commences Screening of Newborns for Sickle Cell Disease
By Modupe Gbadeyanka
The Lagos State government has kicked off an initiative to ensure that every newborn is screened for Sickle Cell Disease within 48 to 72 hours after birth using a simple heel-prick test.
It was gathered that babies identified as being at risk will immediately be placed on preventive care while awaiting confirmatory testing.
The Head of the Haematology Department at the Alimosho General Hospital, Dr Olubukola Orolu, revealed that an estimated 150,000 babies are born annually with Sickle Cell Disease in Nigeria, giving the country one of the highest SCD burdens globally.
She, however, applauded the Lagos State Government and the Clinton Health Access Initiative (CHAI) for introducing the state-wide newborn screening programme, describing it as a major step towards reducing childhood deaths associated with the disease.
The commencement of this scheme coincides with the 2026 World Sickle Cell Day, themed Young Voices Rising for Sickle Cell Disease – Closing the Survival Gap: Equity in Sickle Cell Disease.
It highlights the importance of listening to the experiences and aspirations of young people living with Sickle Cell Disease.
Mrs Orolu noted that SCD warriors are increasingly breaking barriers as advocates, leaders, students and change-makers, adding that their voices have continued to reshape the narrative through advocacy for equitable, patient-centred healthcare, self-care and experience sharing.
She, therefore, called for equal access to quality healthcare, survival opportunities and dignity for everyone living with Sickle Cell Disease.
Also commenting, the chief executive of Alimosho General Hospital, Dr Akinyele Akinlade, described Sickle Cell Disease as an inherited blood disorder that is not contagious, noting that individuals living with the condition are more susceptible to infections.
He advised SCD warriors to stay well hydrated, avoid stress, and protect themselves from extreme cold or heat, as these are common triggers of sickle cell crises, adding that these preventive measures can significantly reduce the frequency and severity of crises.
One of the participants, Ms Borokini Zainab, an SCD warrior and student nurse, expressed appreciation to the organisers for the enlightenment programme.
Sharing her personal journey, she spoke about the challenges of balancing recurrent pain crises with her academic pursuits and personal life. Despite moments of frustration, she encouraged fellow warriors not to lose hope.
“Don’t let sickle cell put you down. Be encouraged from within. Don’t let your dreams be shattered because of this,” she said, adding that her personal experience with Sickle Cell Disease inspired her to pursue a career in nursing so she could support others living with the condition.
Health
Evon Labs Unveils Health-Tech Incubation Initiative HealthX Catalyst
By Aduragbemi Omiyale
A 12-week health-tech incubation programme tailored for early-stage founders in Nigeria has been introduced by an innovation and venture-building platform, Evon Labs.
This initiative, known as HealthX Catalyst, will help participants to create scalable, investable solutions for Africa’s urgent healthcare issues.
The programme is underway, with 12 selected founders nearing the final weeks of intensive incubation, ending with a Demo Day on June 24, 2026, at the UNDP innovation centre in Lagos, where the small business owners will present their solutions to an audience of investors, healthcare leaders, development organisations, and technology partners.
The initiative selects early-stage healthcare founders and immerses them in a structured 12-week development process. Throughout this period, participants receive personalised and group mentorship from seasoned professionals across the healthcare, technology, and business sectors.
They also receive structured support for startup development, including refining business models, developing value propositions, and validating markets.
Additionally, participants gain access to a network of healthcare practitioners, sector experts, and industry leaders, along with targeted investment-readiness assistance to prepare them to engage with investors and strategic partners after the programme.
The result is a cohort of founders who move through the programme not simply with a refined pitch, but with a validated business model, a stronger professional network, and a clear pathway to growth.
To accelerate the most promising solutions beyond the programme, monetary grants will be awarded to the top three founders to support product development, pilot implementation, market validation, and early-stage scaling.
It was learned that HealthX Catalyst was developed in response to a structural gap in the African health-tech ecosystem.
Across the continent, a growing number of entrepreneurs are building solutions to healthcare problems from access and diagnostics to service delivery and health data infrastructure. Yet many of these early-stage ideas fail to progress beyond concept, not for lack of vision, but for lack of structured support: mentorship, startup development frameworks, industry access, and early-stage funding pathways. HealthX Catalyst was built to provide exactly that.
“Africa does not have a shortage of healthcare innovators. What it has lacked is the infrastructure to turn its ideas into sustainable businesses. HealthX Catalyst is that infrastructure, a serious, structured programme designed to take founders from early-stage ideas to investable startups.
“What we are seeing from this first cohort is exactly what we set out to create: founders who are not just building products, but building businesses that can scale and create lasting impact,” the founder of Evon Labs, Ms Isioma Udeozo, said of the unveiling of HealthX Catalyst.
The partners of the programme are the United Nations Development Programme (UNDP), Odua Investment Company Limited (OICL), Washington University of St Louis, Missouri, Lagos State Employment Trust Fund (LSETF), and Brooks Insights.
Health
Binance Promises $250,000 for Ebola in DR Congo, Uganda
By Aduragbemi Omiyale
The sum of $250,000 in humanitarian funding is to be provided by Binance to support the frontline response to the ongoing Ebola disease outbreak in the Democratic Republic of Congo (DRC) and Uganda.
The cryptocurrency exchange said the funds would be used to enable rapid response in high-risk and underserved areas, where access to healthcare infrastructure, protective resources, and timely public health information remains limited.
The money will be shared equally between the Uganda Red Cross Society and Doctors Without Borders / Médecins Sans Frontières (MSF), supporting urgent interventions in affected and high-risk communities.
Binance’s contribution will help strengthen emergency medical care and treatment, community awareness and prevention campaigns, contact tracing and containment support, and the provision of sanitation supplies and protective equipment for frontline workers.
By supporting both immediate response activities and preventative education, Binance aims to contribute to reducing transmission and strengthening community resilience.
“Communities across Africa continue to show extraordinary resilience in the face of complex challenges, but frontline responders should not have to face crises like this alone,” the co-chief executive of Binance, Mr Richard Teng, said.
“The teams working to contain the Ebola disease outbreak are delivering vital, life-saving support under incredibly difficult conditions.
“We are proud to support both the Uganda Red Cross Society and Doctors Without Borders as they work to protect vulnerable populations, strengthen local response efforts, and deliver urgent care where it is needed most,” he added.
Also commenting, the Secretary General for the Uganda Red Cross Society, Mr Robert Kwesiga, said, “Strong partnerships are essential during public health emergencies since we are not able to manage the outbreak alone.
“The support from Binance comes in so timely and handy, and will help us respond more rapidly, reach more at-risk communities, and reinforce the frontline services needed to help contain the outbreak and save lives.”
The MSF Emergency Programme Manager, Trish Newport, while speaking on the initiative, said, “The number of cases and deaths we are seeing in such a short timeframe, combined with the spread across several health zones and now across the border, is extremely concerning. In Ituri, many people already struggle to access healthcare and live with ongoing insecurity, making rapid action critical to prevent the outbreak from escalating further.”
Caused by the Bundibugyo virus, for which there is no approved vaccine or treatment, this Ebola disease outbreak has placed acute pressure on already fragile health systems in eastern DRC and the wider region.
Local authorities, international agencies, and humanitarian organisations are racing to contain it and protect affected communities.
Binance’s support is intended to reinforce these efforts at a critical moment. It reflects the company’s broader commitment to supporting communities across Africa through programmes focused on education, financial inclusion, digital skills development, and community empowerment.
In this case, Binance is extending that commitment to urgent humanitarian and public health needs by working alongside trusted organisations with deep frontline expertise.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn


